For example, a recombinant adenovirus vector vaccine delivering the LMP2 antigen can dose-dependently increase the proportion of LMP2-specific CD3+/CD4+ T lymphocytes in the peripheral blood of NPC patients [205]. This evidence concerns the gene PSMB9 and nasopharyngeal carcinoma.